UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Affimed N.V. (AFMD)

Affimed N.V. (AFMD)
0.8780 x 5 1.0000 x 1
Post-market by (Cboe BZX)
0.8970 +0.0119 (+1.34%) 03/20/25 [NASDAQ]
0.8780 x 5 1.0000 x 1
Post-market 0.8970 unch (unch) 16:00 ET
Quote Overview for Thu, Mar 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8800
Day High
0.9028
Open 0.8850
Previous Close 0.8851 0.8851
Volume 101,300 101,300
Avg Vol 73,765 73,765
Stochastic %K 22.34% 22.34%
Weighted Alpha -79.59 -79.59
5-Day Change +0.0210 (+2.40%) +0.0210 (+2.40%)
52-Week Range 0.8500 - 8.9500 0.8500 - 8.9500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,442
  • Shares Outstanding, K 16,100
  • Annual Sales, $ 8,960 K
  • Annual Income, $ -114,660 K
  • EBIT $ -76 M
  • EBITDA $ -74 M
  • 60-Month Beta 2.22
  • Price/Sales 14.41
  • Price/Cash Flow N/A
  • Price/Book 0.77
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.50
  • Most Recent Earnings $-1.03 on 11/14/24
  • Next Earnings Date 03/27/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.91
  • Number of Estimates 2
  • High Estimate -0.89
  • Low Estimate -0.93
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8500 +5.53%
on 03/14/25
Period Open: 1.0200
1.0600 -15.38%
on 02/27/25
-0.1230 (-12.06%)
since 02/20/25
3-Month
0.8500 +5.53%
on 03/14/25
Period Open: 1.1900
1.5400 -41.75%
on 01/02/25
-0.2930 (-24.62%)
since 12/20/24
52-Week
0.8500 +5.53%
on 03/14/25
Period Open: 5.2900
8.9500 -89.98%
on 06/12/24
-4.3930 (-83.04%)
since 03/20/24

Most Recent Stories

More News
Affimed N.V. Reports Promising 40% Complete Remission Rate for AFM28 in Heavily Pretreated R/R AML Patients

AFM28 shows 40% complete remission rate in R/R AML patients with manageable safety profile in Phase 1 trial.Quiver AI SummaryAffimed N.V. announced promising results for its bispecific innate cell engager,...

AFMD : 0.8970 (+1.34%)
Affimed N.V. Reports Encouraging Efficacy of Acimtamig Combined with AlloNK® in R/R Classical Hodgkin Lymphoma at ASH Annual Meeting

Acimtamig with AlloNK® shows 86% response rate in relapsed/refractory classical Hodgkin lymphoma, with manageable safety.Quiver AI SummaryAffimed N.V. announced promising results from a study combining...

AFMD : 0.8970 (+1.34%)
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy

Affimed N.V. AFMD announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its pipeline candidate, acimtamig (AFM13).The regulatory body granted the RMAT designation...

AFMD : 0.8970 (+1.34%)
CSTL : 20.07 (-2.29%)
SPRO : 0.7776 (+1.65%)
ARTV : 4.04 (-9.01%)
Affimed Receives FDA RMAT Designation for Acimtamig and Artiva’s AlloNK® in Relapsed/Refractory Hodgkin Lymphoma Treatment

Affimed's acimtamig and Artiva's AlloNK® receive FDA RMAT designation for treating relapsed/refractory Hodgkin Lymphoma based on promising early data.Quiver AI SummaryAffimed N.V. announced that the U.S....

AFMD : 0.8970 (+1.34%)
Affimed N.V. Completes Enrollment in NSCLC Cohort and Prepares for Data Presentations at ASH 2024

Affimed N.V. reports on clinical trials, financial results, and updates on cash position through Q4 2025.Quiver AI SummaryAffimed N.V. announced the completion of enrollment in the EGFR wild-type non-small...

AFMD : 0.8970 (+1.34%)
Affimed N.V.: Q3 Earnings Snapshot

Affimed N.V.: Q3 Earnings Snapshot

AFMD : 0.8970 (+1.34%)
Affimed N.V.: Q2 Earnings Snapshot

Affimed N.V.: Q2 Earnings Snapshot

AFMD : 0.8970 (+1.34%)
Affimed N.V.: Q1 Earnings Snapshot

Affimed N.V.: Q1 Earnings Snapshot

AFMD : 0.8970 (+1.34%)
Affimed N.V.: Q3 Earnings Snapshot

Affimed N.V.: Q3 Earnings Snapshot

AFMD : 0.8970 (+1.34%)
Affimed N.V.: Q2 Earnings Snapshot

Affimed N.V.: Q2 Earnings Snapshot

AFMD : 0.8970 (+1.34%)

Business Summary

Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V.,...

See More

Key Turning Points

3rd Resistance Point 0.9293
2nd Resistance Point 0.9161
1st Resistance Point 0.9065
Last Price 0.8970
1st Support Level 0.8837
2nd Support Level 0.8705
3rd Support Level 0.8609

See More

52-Week High 8.9500
Fibonacci 61.8% 5.8558
Fibonacci 50% 4.9000
Fibonacci 38.2% 3.9442
Last Price 0.8970
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals